Reported 1 day ago
LifeSci Capital analyst Sam Slutsky has reaffirmed a Buy rating for Immunovant, Inc. (NASDAQ:IMVT) with a price target of $50, citing the significant market potential for its drug IMVT-1402, targeted at treating Graves’ disease. This condition affects around one million patients in the US, and existing treatments often fall short. The analyst emphasized IMVT-1402's novel approach in reducing pathogenic IgG autoantibodies, indicating strong demand for such targeted therapies. With ongoing trials supporting their optimistic view, Immunovant aims to address substantial unmet medical needs in autoimmune diseases.
Source: YAHOO